[Efficacy and safety of paritaprevir/ritonavir/ombitasvir combined with dasabuvir in non-cirrhotic Asian adult patients with newly diagnosed and treated chronic HCV genotype 1b infection: a randomized, double-blind, placebo-controlled study - China data].
Wei L, Cheng J, Luo J, Li ZP, Duan JL, Hou JD, Jia MX, Zhang Y, Huang Q, Xie GJ, Wang DL, Yang W, Zhao CY, Zhao G, Tang SM, Lin GZ, Gong JJ, Niu ZL, Gao JF, Sarah KB, Linda F, Niloufar M, Wang Y, Wang J.
Wei L, et al. Among authors: tang sm.
Zhonghua Gan Zang Bing Za Zhi. 2018 May 20;26(5):359-364. doi: 10.3760/cma.j.issn.1007-3418.2018.05.009.
Zhonghua Gan Zang Bing Za Zhi. 2018.
PMID: 29996204
Clinical Trial.
Chinese.